BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Hyun Chul Lim, Yong Jae Lee, Byoungrak An, Seung Woo Lee, Yong Chan Lee, Byung Soo Moon. Rifabutin-based High-dose Proton-pump Inhibitor and Amoxicillin Triple Regimen as the Rescue treatment forHelicobacter pyloriHelicobacter 2014; 19(6): 455 doi: 10.1111/hel.12147
2
Javier P Gisbert. &ldquo;Rescue&rdquo; regimens after <italic>Helicobacter pylori</italic> treatment failureWorld Journal of Gastroenterology 2008; 14(35): 5385-5402 doi: 10.3748/wjg.14.5385
3
Javier P. Gisbert. Review: Second-line rescue therapy ofHelicobacter pyloriinfectionTherapeutic Advances in Gastroenterology 2009; 2(6): 331 doi: 10.1177/1756283X09347109
4
Juntaro Matsuzaki, Hidekazu Suzuki, Hitoshi Tsugawa, Toshihiro Nishizawa, Toshifumi Hibi. Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapyJournal of Gastroenterology and Hepatology 2010; 25: S7 doi: 10.1111/j.1440-1746.2010.06245.x
5
Quan Zhou, Ling-Ling Zhu, Xiao-Feng Yan, Wen-Sheng Pan, Su Zeng. Drug utilization of clarithromycin for gastrointestinal disease treatmentWorld Journal of Gastroenterology 2008; 14(39): 6065-6071 doi: 10.3748/wjg.14.6065
6
Vincent Cattoir, Juliette Nectoux, Christine Lascols, Lionel Deforges, Jean-Charles Delchier, Francis Megraud, Claude-James Soussy, Emmanuelle Cambau. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibilityInternational Journal of Antimicrobial Agents 2007; 29(4): 389 doi: 10.1016/j.ijantimicag.2006.11.007
7
Yoshihiro Hirata, Tomoya Ohmae, Ayako Yanai, Kosuke Sakitani, Yoku Hayakawa, Shuntaro Yoshida, Takafumi Sugimoto, Yuzo Mitsuno, Masao Akanuma, Yutaka Yamaji, Keiji Ogura, Shin Maeda, Kazuhiko Koike. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in JapanInternational Journal of Antimicrobial Agents 2012; 39(4): 352 doi: 10.1016/j.ijantimicag.2011.12.002
8
Elżbieta Karczewska, Izabela Wojtas-Bonior, Edward Sito, Małgorzata Zwolińska-Wcisło, Alicja Budak. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern PolandPharmacological Reports 2011; 63(3): 799 doi: 10.1016/S1734-1140(11)70592-8
9
Sang Kyu Lee, Sang Woo Lee, Jae Yeon Park, Bo Sung Kwon, Seung Young Kim, Jong Jin Hyun, Jeong Han Kim, Sung Woo Jung, Ja Seol Koo, Hyung Joon Yim, Jai Hyun Choi. Effectiveness and Safety of Repeated Quadruple Therapy in Helicobacter pylori Infection After Failure of Second-line Quadruple TherapyHelicobacter 2011; 16(5): 410 doi: 10.1111/j.1523-5378.2011.00870.x
10
Hafez Fakheri, Zohreh Bari, Hossein Sardarian. A modified Bismuth-Containing Quadruple Therapy Including a Short Course of Furazolidone for Helicobacter pylori Eradication After Sequential Therapy FailureHelicobacter 2012; 17(4): 264 doi: 10.1111/j.1523-5378.2012.00946.x
11
Myung Ho Jeong, Jun-Won Chung, Sang Jin Lee, Minsu Ha, Seok Hoo Jeong, Sunyoung Na, Byung Soo Na, Sung Keun Park, Yoon Jae Kim, Kwang An Kwon, Kwang Il Ko, Yunjeong Jo, Ki Baik Hahm, Hwoon-Yong Jung. Comparison of Rifabutin- and Levofloxacin-based Third-line Rescue Therapies forHelicobacter pyloriThe Korean Journal of Gastroenterology 2012; 59(6): 401 doi: 10.4166/kjg.2012.59.6.401
12
Nuno Almeida, José M. Romãozinho, Maria M. Donato, Cristina Luxo, Olga Cardoso, Maria A. Cipriano, Carol Marinho, Carlos Sofia. Triple Therapy with High-Dose Proton-Pump Inhibitor, Amoxicillin, and Doxycycline Is Useless forHelicobacter pyloriEradication: A Proof-of-Concept StudyHelicobacter 2014; 19(2): 90 doi: 10.1111/hel.12106
13
Krit Suknuntha, Vimon Tantishaiyakul, Nimit Worakul, Wirach Taweepreda. Characterization of muco- and bioadhesive properties of chitosan, PVP, and chitosan/PVP blends and release of amoxicillin from alginate beads coated with chitosan/PVPDrug Development and Industrial Pharmacy 2011; 37(4): 408 doi: 10.3109/03639045.2010.518149
14
Nastaran Farzi, Abbas Yadegar, Amir Sadeghi, Hamid Asadzadeh Aghdaei, Sinéad Marian Smith, Josette Raymond, Hidekazu Suzuki, Mohammad Reza Zali. High Prevalence of Antibiotic Resistance in Iranian Helicobacter pylori Isolates: Importance of Functional and Mutational Analysis of Resistance Genes and Virulence GenotypingJournal of Clinical Medicine 2019; 8(11): 2004 doi: 10.3390/jcm8112004
15
Toshihiro Nishizawa, Hidekazu Suzuki, Toshifumi Hibi. Quinolone-Based Third-Line Therapy for Helicobacter pylori EradicationJournal of Clinical Biochemistry and Nutrition 2009; 44(2): 119 doi: 10.3164/jcbn.08-220R
16
M. Gómez-Burgaz, B. García-Ochoa, S. Torrado-Santiago. Chitosan–carboxymethylcellulose interpolymer complexes for gastric-specific delivery of clarithromycinInternational Journal of Pharmaceutics 2008; 359(1-2): 135 doi: 10.1016/j.ijpharm.2008.03.042
17
György M Buzás, Jolán Józan. Nitrofuran-based regimens for the eradication of Helicobacter pylori infectionJournal of Gastroenterology and Hepatology 2007; 22(10): 1571 doi: 10.1111/j.1440-1746.2007.05082.x
18
Elżbieta Karczewska, Karolina Klesiewicz, Iwona Skiba, Izabela Wojtas-Bonior, Edward Sito, Krzysztof Czajecki, Małgorzata Zwolińska-Wcisło, Alicja Budak. Variability in Prevalence ofHelicobacter pyloriStrains Resistant to Clarithromycin and Levofloxacin in Southern PolandGastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/418010
19
Lukas Hleba, Ivana Charousova, Miroslava Cisarova, Anton Kovacik, Jan Kormanec, Juraj Medo, Matej Bozik, Sona Javorekova. Rapid identification of Streptomyces tetracycline producers by MALDI-TOF mass spectrometryJournal of Environmental Science and Health, Part A 2018; 53(12): 1083 doi: 10.1080/10934529.2018.1474581